Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- DIAGNOSTIC NEWS IN BRIEF
December 17, 2001
- 17th Quality Reevaluation to Start on 18 Mono-drugs, 8 Combinations
December 17, 2001
- Sephora to Withdraw from Japan
December 17, 2001
- Quality Reevaluation Completed for Drugs Accounting for 60% of Total Market
December 17, 2001
- Matsumotokiyoshi: Sales, Net Profits Increase 11%, 46.1%, Respectively
December 17, 2001
- REGULATORY NEWS IN BRIEF
December 17, 2001
- Kraft: Dispensing Business Boosts Sales by 16.8%
December 17, 2001
- FTC Issues Recommendation to 9 Wholesalers in the Tohoku Region
December 17, 2001
- BioZak Japan Established to Supply Mfg. Technology on Hepatitis C Agents
December 17, 2001
- Fukuda Denshi to Manufacture ECG in China
December 17, 2001
- Eli Lilly, Chugai to Dissolve Their JV
December 17, 2001
- Hitachi Medical Develops Lung Cancer Diagnosis Support System
December 17, 2001
- EPS: CRO, SMO Businesses Boost Sales by 42.2%
December 17, 2001
- ISI Provides Medical, Pharmaceutical Literature Search Services
December 17, 2001
- AstraZeneca to Launch New Corticosteroid Inhaler, Pulmicort Turbuhaler
December 17, 2001
- JAPANESE LANGUAGE BOOKS
December 17, 2001
- Differences in Culture Prevent Tanabe, Taisho from Getting Together
December 17, 2001
- Chugai to Become Member of Roche Group
December 17, 2001
- BUSINESS NEWS IN BRIEF
December 10, 2001
- Inabata to Gear Up Drug, Health Food Business
December 10, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…